Tvardi Therapeutics

STAT3 inhibitors

Also Clin1b/Clin2 breast cancer, Clin1 solid tumors, Clin0 fibrosis; TTI-102 Clin0 undisclosed

Tvardi Therapeutics is focused on the treatment of cancer, chronic inflammatory, and fibrotic diseases, through the targeting of the STAT3 signaling pathway. This pathway plays a pivotal role in the promotion of tumor growth, suppression of the immune system's response to cancer, and the pathogenesis of inflammatory and fibrotic conditions. Tvardi's aims to inhibit this pathway to allow the targeting of cancer cells, reversal of fibrosis, and restoration of normal immune function. With a commitment to advancing precision medicine, Tvardi Therapeutics offers a promising avenue for treating a wide range of inflammatory, fibrotic, and oncolytic conditions, as well as improving patient outcomes.